Header Logo


Kate Lapane to Cholinesterase Inhibitors

This is a "connection" page, showing publications Kate Lapane has written about Cholinesterase Inhibitors.
Connection Strength

  1. Ott BR, Lapane KL. Mortality in donepezil-treated patients. J Am Geriatr Soc. 2004 Aug; 52(8):1412-3; author reply 1413.
    View in: PubMed
    Score: 0.288
  2. Ott BR, Lapane KL. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. J Am Geriatr Soc. 2002 Jan; 50(1):35-40.
    View in: PubMed
    Score: 0.241
  3. Maclagan LC, Bronskill SE, Guan J, Campitelli MA, Herrmann N, Lapane KL, Hogan DB, Amuah JE, Seitz DP, Gill SS, Maxwell CJ. Predictors of Cholinesterase Discontinuation during the First Year after Nursing Home Admission. J Am Med Dir Assoc. 2018 11; 19(11):959-966.e4.
    View in: PubMed
    Score: 0.192
  4. Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging. 2010 Jun 01; 27(6):435-49.
    View in: PubMed
    Score: 0.108
  5. Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother. 2009 Apr; 7(2):74-83.
    View in: PubMed
    Score: 0.100
  6. Gifford DR, Lapane KL, Gambassi G, Landi F, Mor V, Bernabei R. Tacrine use in nursing homes: implications for prescribing new cholinesterase inhibitors. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. Neurology. 1999 Jan 15; 52(2):238-44.
    View in: PubMed
    Score: 0.049
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.